Another active area of research in the laboratory focuses on unraveling the mechanisms behind maladaptive, or pathological, and adaptive, or physiological, cardiac hypertrophy. In response to certain ...

Rapamycin inhibits the growth factor mTOR (mammalian target of rapamycin), which is activated by both physiological and pathological hypertrophy. Inhibition of mTOR by rapamycin reduces ...

Cardiac hypertrophy can be classified into two categories: physiological and pathological. Physiological hypertrophy is reversible, leads to normal or enhanced cardiac function, and typically occurs ...

The changes in cardiovascular physiology must be differentiated ... and left ventricular hypertrophy, as well as other changes in the left ventricular wall that prolong relaxation of the left ...

Cardiac hypertrophy is the abnormal enlargement ... such as extracellular matrix. Causes can be physiological for example, the amount of exercise performed by an athlete or pathological ...

Aim Differentiating physiological cardiac hypertrophy from pathology is challenging when the athlete presents with extreme anthropometry. While upper normal limits exist for maximal left ventricular ...

The presence of left ventricule hypertrophy (LVH) due to arterial hypertension may impair atrial function ... This study investigated whether mechanical dysfunction in the left atrium (LA) is present ...

High-intensity exercise raises sudden cardiac death risk in young hypertrophic cardiomyopathy patients, independent of ...

Researchers assessed physiologic changes of the spine as well as the frequency of low back pain among astronauts during and after spaceflight.